This document is a publication of a new patent application filed with the USPTO. It describes an improved adenovirus formulation comprising a recombinant adenovirus, a citrate buffer, a cyclodextrin compound, and a salt. Key characteristics include a pH range of 5.5 to 6.5 and the absence of non-ionic detergent. The application also claims a method for preserving adenoviruses using this specific formulation.

While this is a patent application and not a regulatory rule, it signals potential future developments in adenovirus-based therapeutics and preservation methods. Companies involved in the development or manufacturing of adenoviruses should be aware of this filing as it may impact future intellectual property landscapes and product development strategies in the pharmaceutical sector. No immediate compliance actions are required, but monitoring patent filings is crucial for R&D and legal teams.